A rare cause of diarrhoea: uncommon effect of an ordinary medication
DOI:
https://doi.org/10.32385/rpmgf.v38i5.13360Keywords:
Diarrhoea, Arterial hypertension, Angiotensin II receptor blockers, Olmesartan, Adverse effectsAbstract
Introduction: Arterial hypertension is a chronic condition and one of the main risk factors for cardiovascular disease. Therefore, patients presenting with this disorder benefit from regular follow-ups with their general practitioner/family doctor (FD). Blood pressure control can be achieved with lifestyle measures alone or by resorting simultaneously to pharmacological treatment. Among pharmacological options, angiotensin II receptor blockers (ARB) stand out for being commonly used due to their anti-hypertensive effect and safety profile, albeit they can rarely cause severe chronic diarrhoea. This case report intends to present a rare diagnosis and sharpen FD to a new diagnostic hypothesis in the face of chronic diarrhoea.
Case report: A 65-year-old woman, with a personal history of arterial hypertension treated with olmesartan 20mg since 2012 and no other relevant personal history. The patient presented with a one-month history of diarrhoea entailing several medical evaluations. Along with abdominal pain, nausea, vomiting, asthenia, and weight loss. Due to an inconclusive outpatient investigation and lack of clinical response to the multiple empirical treatments, the patient was proposed for hospital admission for further etiological study. While hospitalized, olmesartan was discontinued resulting in symptom resolution, which lead to patient discharge with the diagnosis of sprue-like enteropathy.
Conclusion: This case intends to emphasize the importance of a complete and detailed medical history, recall the main steps in the investigation of chronic diarrhoea and disclose a rare diagnosis of sprue-like enteropathy olmesartan-induced. According to the European definition of general practice/family medicine, the FD is responsible for the longitudinal continuity of care which will involve the reassessment and monitoring of the clinical condition. Furthermore, once faced with this diagnosis, FD is encouraged to overcome the challenge of ulterior blood pressure control.
Downloads
References
Cardoso J, Miranda G, Gonçalves MI, Teixeira A, Tjeng R, Ballesteros R. Elevação aguda da pressão arterial nos doentes hospitalizados [High blood pressure in hospitalized patients]. Rev Port Hipertens Risco Cardiovasc. 2020;(80):6-10. Portuguese
Direção-Geral da Saúde. Abordagem terapêutica da hipertensão arterial: norma nº 026/2011, de 29/09/2011, atualizada em 19/03/2013. Lisboa: DGS; 2013.
World Health Organization. WHO guidelines on physical activity and sedentary behaviour [homepage]. Geneva: WHO; 2020 Nov 25. Available from: https://www.who.int/publications/i/item/9789240015128
Makri A, Florentin M, Elisaf MS, Liamis G. Significant weight loss in a patient taking olmesartan: an unusual case report. Curr Drug Saf. 2019;14(3):238-41.
National Institute of Diabetes and Digestive and Kidney Diseases. Angiotensin II receptor antagonists. In: LiverTox: clinical and research information on drug-induced liver injury [homepage]. Bethesda: NIDDK; 2012 [updated 2017 Jan 13; cited 2021 Sep 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548642/
Sher M, Murray M, McGuire L, Fitzpatrick S, Kurtkoti J. Olmesartan-induced enteropathy: a rare side effect of a common medication. Cureus. 2019;11(12):e6400.
Kamal A, Fain C, Park A, Wang P, Gonzalez-Velez E, Leffler DA, et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep. 2019;7(3):162-7.
Infarmed. Prontuário terapêutico online [homepage]. Lisboa: Infarmed; 2016 [cited 2021 Oct 02]. Available from: http://app10.infarmed.pt/prontuario/frameprimeiracapitulos.html
Menne J, Haller H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc. 2012;87(12):1230-1.
Galanopoulos M, Varytimiadis L, Tsigaridas A, Karatzas PS, Archavlis E, Viazis N, et al. Small bowel enteropathy associated with olmesartan medoxomil treatment. Ann Gastroenterol. 2017;30(1):131-3.
Arasaradnam RP, Brown S, Forbes A, Fox MR, Hungin P, Kelman L, et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018;67(8):1380-99.
Naik DK, Martelli MG, Hernandez Gonzalo D, Sharma AK, Pannu D. An atypical case of chronic diarrhoea: olmesartan-induced sprue-like enteropathy. BMJ Case Rep. 2015;2015:bcr2015212318.
Verstockt B, Deleenheer B, Sermon F, Van Der Steen K, Vandervoort J. An unusual cause of severe, persistent diarrhoea. Acta Gastroenterol Belg. 2017;80(3):416-8.
Modesto J, González P, Terry O, Leturia I, Aguiar B, Elejalde I. Enteropatía asociada a olmesartán: atención a un fenómeno iatrogénico emergente [Olmesartan-associated enteropathy: attention to an emerging iatrogenic phenomenon]. Anales Sis San Navarra. 2017;40(2):291-4. Spanish
WONCA. The European definition of GP/FM [homepage]. Ljubljana: WONCA; 2002 [cited 2021 Sep 28]. Available from: https://www.woncaeurope.org/page/definition-of-general-practice-family-medicine
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Portuguese Journal of Family Medicine and General Practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.
